Correlation of airway obstruction and patient-reported endpoints in clinical studies

被引:74
作者
Shingo, S
Zhang, J
Reiss, TF
机构
[1] Merck Res Labs, Dept Clin Biostat, Rahway, NJ 07065 USA
[2] Merck Res Labs, Dept Pulm & Immunol, Rahway, NJ 07065 USA
关键词
as-needed beta-agonist use; asthma; correlation; FEV1; PEF; symptom;
D O I
10.1183/09031936.01.17202200
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
To establish the correlation among asthma efficacy parameters over a long period, data from over 1500 patients in two one-year asthma clinical trials with montelukast, a Cys-LT1 antagonist,were analysed. Airway obstruction measurements, forced expiratory volume: in one second (FEV1) and peak expiratory flow (PEF), were measured at clinic visits. Patients recorded daytime symptom score, "as-needed" beta -agonist use, and PEF on a daily basis. Relationships among these parameters at baseline and during the one-year treatment period were established by correlation analyses. Multiple correlations between the airway obstruction (FEV1 and PEF) and patient-reported measurements were evaluated by canonical correlation analysis, Pairwise correlations of the efficacy parameters over a one-year time period were stable, Canonical correlation between the airway obstruction and patient-reported asthma efficacy endpoints mas low, indicating that each category of endpoints measures a distinctively different aspect of the disease. It appears that at least one endpoint from each category should be used in asthma clinical studies.
引用
收藏
页码:220 / 224
页数:5
相关论文
共 12 条
[11]  
SHINGO S, 1997, AM J RESP CRIT CARE, V155, pA889
[12]  
ZHANG J, 1997, AM J RESP CRIT CARE, V155, pA892